Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

Michael Dagher; Felicia Ruffin; Steven Marshall; Magdalena Taracila; Robert A Bonomo; Rachel Reilly; Vance G Fowler Jr; Joshua T Thaden

doi:10.1093/ofid/ofaa150

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

Open Forum Infect Dis. 2020 May 5;7(5):ofaa150. doi: 10.1093/ofid/ofaa150. eCollection 2020 May.

Authors

Michael Dagher¹, Felicia Ruffin¹, Steven Marshall^{2

3

4

5}, Magdalena Taracila^{2

3

4

5}, Robert A Bonomo^{2

3

4

5}, Rachel Reilly⁶, Vance G Fowler Jr¹, Joshua T Thaden¹

Affiliations

¹ Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
² Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
³ Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
⁴ Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
⁵ United States of America CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
⁶ Department of Orthopedic Surgery, Duke University School of Medicine, Durham, North Carolina, USA.

Abstract

Cefiderocol is a novel catechol siderophore cephalosporin antibiotic developed to treat resistant gram-negative infections. We describe its successful use as rescue therapy, combined with surgical debridement, to treat a patient with osteomyelitis due to extensively drug-resistant Acinetobacter baumannii. Bacterial whole-genome sequencing identified the strain and antibiotic resistance determinants.

Keywords: Acinetobacter baumannii; antimicrobial resistance; cefiderocol; osteomyelitis.

Grants and funding

K24 AI093969/AI/NIAID NIH HHS/United States